Superluminal Medicines Secures $60M for AI Platform
Superluminal Medicines has successfully raised sixty million dollars in a Series B financing round, according to a report by Unite.AI. The company applies artificial intelligence and machine learning methods to drug discovery, targeting G protein-coupled receptors across various therapeutic areas including obesity.
The fresh capital will be deployed to scale the platform and expand the pipeline of targeted medicines. By utilizing advanced computational tools to map protein structures and design novel compounds, Superluminal aims to accelerate preclinical development timelines. The financing round was backed by multiple investors supporting the application of generative biology in pharmaceutical R&D.
As builders in the artificial intelligence and biotechnology sectors continue to converge, companies like Superluminal are utilizing automated generation systems to bypass traditional trial and error methods in drug design. The new funding will support the growth of the technical team and further infrastructure investments required to advance its lead programs toward clinical trials.
Based on reporting by www.unite.ai.
